Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.22 USD
Change Today +0.64 / 8.44%
Volume 9.0M
NVAX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

novavax inc (NVAX) Snapshot

Open
$7.68
Previous Close
$7.58
Day High
$8.30
Day Low
$7.68
52 Week High
03/20/15 - $9.95
52 Week Low
04/15/14 - $3.34
Market Cap
2.2B
Average Volume 10 Days
6.8M
EPS TTM
$-0.36
Shares Outstanding
264.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVAVAX INC (NVAX)

novavax inc (NVAX) Related Businessweek News

No Related Businessweek News Found

novavax inc (NVAX) Details

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase II clinical trials, as well as pediatric respiratory syncytial virus candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase I clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate, which is pre-clinical trial; and seasonal influenza vaccine candidate that is Phase III clinical trial, as well as rabies G protein vaccine candidate, which is in Phase 1/2 clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. has a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland.

308 Employees
Last Reported Date: 02/27/15
Founded in 1987

novavax inc (NVAX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $448.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $156.3K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $371.9K
Senior Vice President of Global Manufacturing...
Total Annual Compensation: $284.5K
Compensation as of Fiscal Year 2013.

novavax inc (NVAX) Key Developments

Novavax Seeks Acquisitions

Novavax, Inc. (NasdaqGS:NVAX) intends to use the proceeds for process development expenditures and capital expenditures, as well as acquisitions and other strategic purposes.

Novavax, Inc. Appoints Brian Rosen as Vice President, Government Affairs and Policy

Novavax, Inc. announced the appointment of Brian Rosen to the position of Vice President, Government Affairs and Policy. Mr. Rosen will be responsible for leading government affairs and policy efforts that are instrumental to patient access to Novavax vaccines. Mr. Rosen's efforts will be focused on the company's lead product candidates, including its RSV vaccine franchise, and quadrivalent seasonal and pandemic influenza vaccine candidates. Mr. Rosen comes to Novavax with over 20 years of industry and patient advocacy experience, the vast majority of which he spent engaged in government affairs, advocacy, reimbursement and policy work. He was most recently the Chief Policy, Advocacy and Patient Access Officer for the Leukemia & Lymphoma Society, where he oversaw all legislative and regulatory efforts and the delivery of patient services nationwide.

Novavax, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 09:00 AM

Novavax, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 09:00 AM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France. Speakers: Russell P Wilson, Senior VP, Business Development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVAX:US $8.22 USD +0.64

NVAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celldex Therapeutics Inc $27.17 USD +1.21
Dynavax Technologies Corp $22.70 USD +0.33
Inovio Pharmaceuticals Inc $8.29 USD +0.195
Progenics Pharmaceuticals Inc $5.79 USD +0.08
ZIOPHARM Oncology Inc $11.45 USD +0.335
View Industry Companies
 

Industry Analysis

NVAX

Industry Average

Valuation NVAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 63.9x
Price/Book 8.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 66.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVAVAX INC, please visit www.novavax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.